NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-08-31
Reading IDXX? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Intact: The reason to own it still holds.
Idexx grows revenue about 10% a year, led by 14% growth in CAG Diagnostics recurring revenue. Profit margins stay strong near 32%. The company raised its 2026 revenue guidance to about $4.7 billion and EPS outlook to $14.45. Free cash flow remains positive and supports ongoing investments.
Recurring revenue growth could slow if vet visits plateau. Rising costs may pressure profit margins below 31%. Leadership changes and recent soft guidance raise execution risks. If revenue growth falls below 7%, the business model may be weaker than expected.
The stock price is about 28% above our valuation level. Analysts expect roughly 10% revenue growth. Our view is that current estimates are reasonable but leave limited upside given execution risks and valuation.
Breaks if: YoY growth falls below 7% in FY26
Breaks if: EPS falls below $13.00 in FY26
Breaks if: operating margin falls below 30% in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This is a durable compounder with a focus on consistent revenue and earnings growth. The current thesis state is intact, supported by recent strong financial performance and management's commitment to increasing guidance.
The market seems to expect a durable premium for IDXX, reflecting a moderate expectations gap. However, there is a sense of fragility due to weak execution quality, which may not fully justify the premium compared to peers.
Management is on track to increase revenue and EPS guidance, indicating strong operational execution. However, there is a moderate near-term risk of missing expectations, as recent earnings surprises have been trending down.
The long-term thesis hinges on maintaining momentum in the healthcare sector, particularly if key players continue to perform well. Additionally, any negative shifts in guidance or economic conditions could impact investor confidence.
The most important moves since the prior daily snapshot.
Our read has strengthened. It is supported by the latest earnings beat.
as of 2026-08-31
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: revenue growth falls below 7% in FY26
Overall, IDXX appears to be on solid footing, but it must navigate potential risks carefully. Not investment advice.
